AbCellera Biologics (ABCL) is making significant strides in its drug development pipeline, with several key milestones anticipated in the coming months and years. Here's a summary of the timelines for their drugs in R&D:
- First Two Internal Pipeline Programs: ABCL is on track to file Clinical Trial Applications (CTAs) for its first two internal pipeline programs, ABCL635 and ABCL575, by Q2 of next year1. This indicates an important regulatory submission phase for these programs.
- GMP Manufacturing Facility: The company's GMP manufacturing facility is expected to be operational by 20251. This is a critical infrastructure development that will support the commercialization of their drug candidates.
- Clinical Trials: ABCL is preparing for its first two clinical trials, which are set to commence next year1. This marks the beginning of the clinical validation phase for these drug candidates.
- Partnerships and Collaborations: ABCL has expanded its partnership with Eli Lilly, focusing on co-development collaborations with co-ownership of resulting assets1. This strategic move is likely to accelerate the development and commercialization process of their drug candidates.
In summary, ABCL's drug development pipeline is progressing steadily, with significant milestones expected in the near future. The company's strategic initiatives, including the filing of CTAs for its internal pipeline programs and the expansion of partnerships, underscore its commitment to advancing its drug candidates towards market availability.
11/26/2024 06:23pm
Aime finds your next big stock